404 related articles for article (PubMed ID: 28991247)
21. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
22. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
23. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT).
Maffini E; Labopin M; Blaise D; Ciceri F; Gülbas Z; Deconinck E; Leblond V; Chevallier P; Sociè G; Araujo MC; Koc Y; Savani BN; Gorin NC; Lanza F; Nagler A; Mohty M
Am J Hematol; 2020 Aug; 95(8):892-899. PubMed ID: 32303111
[TBL] [Abstract][Full Text] [Related]
24. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes.
Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Leuk Lymphoma; 2016; 57(1):76-80. PubMed ID: 26084204
[TBL] [Abstract][Full Text] [Related]
27. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
[TBL] [Abstract][Full Text] [Related]
28. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome.
Chien SH; Yao M; Li CC; Chang PY; Yu MS; Huang CE; Tan TD; Lin CH; Yeh SP; Li SS; Wang PN; Liu YC; Gau JP
J Formos Med Assoc; 2021 Dec; 120(12):2144-2152. PubMed ID: 33423899
[TBL] [Abstract][Full Text] [Related]
29. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome.
Itonaga H; Ishiyama K; Aoki K; Aoki J; Ishikawa T; Uchida N; Ohashi K; Ueda Y; Fukuda T; Sakura T; Ohno Y; Iwato K; Okumura H; Kondo T; Ichinohe T; Takanashi M; Atsuta Y; Miyazaki Y
Ann Hematol; 2019 Jun; 98(6):1367-1381. PubMed ID: 30854574
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
[TBL] [Abstract][Full Text] [Related]
31. Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34
Indran T; Das T; Muirhead J; O'Brien M; Swain MI; Cirone B; Widjaja J; Patil S; Curtis DJ
Leuk Res; 2024 Jul; 142():107504. PubMed ID: 38703634
[TBL] [Abstract][Full Text] [Related]
32. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation.
Urbano-Ispizua A; Brunet S; Solano C; Moraleda JM; Rovira M; Zuazu J; de La Rubia J; Bargay J; Caballero D; Díez-Martín JL; Ojeda E; Pérez de Oteiza JP; Ferrá C; Espigado I; Alegre A; de La Serna J; Torres P; Riu C; Odriozola J; Rozman C; Sierra J; García-Conde J; Montserrat E;
Bone Marrow Transplant; 2001 Aug; 28(4):349-54. PubMed ID: 11571506
[TBL] [Abstract][Full Text] [Related]
34. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
[TBL] [Abstract][Full Text] [Related]
35. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
36. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
[TBL] [Abstract][Full Text] [Related]
37. Impact of Toxicity on Survival for Older Adult Patients after CD34
Shah GL; Scordo M; Kosuri S; Herrera DA; Cho C; Devlin SM; Borrill T; Carlow DC; Avecilla ST; Meagher RC; O'Reilly RJ; Jakubowski AA; Papadopoulos EB; Koehne G; Gyurkocza B; Castro-Malaspina H; Shaffer BC; Perales MA; Giralt SA; Tamari R
Biol Blood Marrow Transplant; 2018 Jan; 24(1):142-149. PubMed ID: 28951193
[TBL] [Abstract][Full Text] [Related]
38. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Gao L; Gao L; Gong Y; Zhang C; Chen XH; Zhang X
Leuk Res; 2013 Nov; 37(11):1482-7. PubMed ID: 24054720
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
40. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
De La Serna J; Sanz J; Bermúdez A; Cabrero M; Serrano D; Vallejo C; Gómez V; Moraleda JM; Perez SG; Caballero MD; Conde E; Lahuerta JJ; Sanz G
Bone Marrow Transplant; 2016 Jul; 51(7):961-6. PubMed ID: 26950372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
